Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1596-1607

  Bultmann, Hermann ^a   Teuton, Jeremy ^b   Brandt, Curtis R ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYSTEINE; HEPARAN SULFATE; TAT C PEPTIDE; THIOL DERIVATIVE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIRALITY; CONTROLLED STUDY; HALF LIFE TIME; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TRANSPORT; SYNCYTIUM; VIRION; VIRUS ADSORPTION;

ADSORPTION; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYSTEINE; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE PRODUCTS, TAT; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HIV-1; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS; VIRION;

EID: 34248349875     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01009-06     Document Type: Article

References (64)

1. Akkarawongsa, R., A. E. Cullinan, A. Zinkel, J. Clarin, and C. R. Brandt. 2006. Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry. J. Ocul. Pharmacol. Ther. 22:279-289.
2. Anderson, J. H., H. Jenssen, K. Sandvik, and T. J. Guttenberg. 2004. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparin sulfphate at the cell surface. J. Med. Virol. 74:262-271.
3. Asbell, P. A., S. P. Epstein, J. A. Wallace, D. Epstein, C. C. Stewart, and R. M. Burger. 1998. Efficacy of cobalt chelates in the rabbit eye model for epithelial herpetic keratitis. Cornea 17:550-557.
4. Baghian, A., J. Jaynes, F. Enright, and K. G. Kousoulas. 1997. An amphipathic α-helical synthetic peptide analogue of melittin inhibits herpes simplex virus-1 (HSV-1)-induced cell fusion and virus spread. Peptides 18:117-183.
5. Belaid, A., M. Aouni, R. Khelifa, A. Trabelsi, M. Jemmali, and K. Hani. 2002. In vitro antiviral activity of dermaseptins against herpes simplex virus type 1. J. Med. Virol. 66:229-234.
6. Bernstein, D. I., L. S. Loo, and S. Kohl. 1988. Antibody to cloned HSV glycoproteins B and D plus adult human leukocytes protect neonatal mice from lethal HSV infection. Antivir. Res. 10:279-284.
7. Brown, Z. A., S. Selke, J. Zeh, J. Kopelman, A. Maslow, R. L. Ashley, D. H. Watts, S. Berry, M. Herd, and L. Corey. 1997. The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med. 337:509-515.
8. Bultmann, H., and C. R. Brandt. 2002. Peptides containing membrane transiting motifs inhibit virus entry. J. Biol. Chem. 277:36018-36023.
9. Bultmann, H., J. S. Busse, and C. R. Brandt. 2001. Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 75:2634-2645.
10. Cheshenko, N., B. Del Rosario, C. Woda, D. Marcellino, L. M. Satlin, and B. C. Herald. 2003. Herpes simplex virus triggers activation of calcium-signalling pathways. J. Cell Biol. 163:283-293.
11. Corey, L., A. G. M. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, and S. E. Straus. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 282:331-340.
12. Corey, L., A. Wald, R. Patel, S. L. Sacks, S. K. Tyring, T. Warren, J. M. J. Douglas, J. Paavonen, R. A. Morrow, K. R. Beutner, L. S. Stratchounsky, G. Mertz, O. N. Keene, H. A. Watson, D. Tait, M. Vargas-Cortes, et al. 2004. Once daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350:11-20.
13. Dan, K., K. Miuashita, Y. Seto, S. Fujita, and T. Yamase. 2002. The memory effect of heteropolyoxotungstate (PM-19) pretreatment on infection by herpes simplex virus at the penetration state. Pharmacol. Res. 46:357-362.
14. Davis, W. B., J. A. Taylor, and J. E. Oakes. 1979. Ocular infection with herpes simplex virus type 1: prevention of acute herpetic encephalitis by systemic administration of virus-specific antibody. J. Infect. Dis. 140:534-540.
15. Egal, M., M. Conrad, D. L. Macdonald, W. L. Maloy, M. Motley, and C. A. Genco. 1999. Antiviral effects of synthetic membrane-active peptides on herpes simplex virus, type 1. Int. J. Antimicrob. Agents 13:57-60.
16. Eis-Hubinger, A. M., D. S. Schmidt, and K. E. Schneweis. 1993. Antiglycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. J. Gen. Virol. 74:379-385.
17. Ferrari, M., V. Pellegrini, C. Arcangeli, A. Fittipaldi, M. Giacca, and F. Beltram. 2003. Caveolae-mediated internalization of extracellular HIV-1 fusion proteins visualized in real time. Mol. Ther. 8:284-294.
18. Fittipaldi, A., M. Ferrari, M. Zoppe, C. Arcanqeli, V. Pellegrini, F. Beltram, and M. Giacca. 2003. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 278:34141-34149.
19. Fukuma, M., Y. Seto, and T. Yamase. 1991. In vitro antiviral activity of polyoxotungstate (PM-19) and other polyoxometalates against herpes simplex virus. Antivir. Res. 16:327-339.
20. Geraghty, R. J., C. Krummenacher, G. Cohen, R. J. Eisenberg, and P. G. Spear. 1998. Entry of alphaherpesviruses mediated by poliovirus receptor related protein 1 and poliovirus receptor. Science 280:1618-1620.
21. Goldstein, D. J., and S. K. Weller. 1998. Herpes simplex virus type-1 ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62:196-205.
22. Gong, Y., B. Matthews, D. Cheung, T. Tam, I. Gadawski, D. Leung, G. Holan, J. Raff, and S. L. Sacks. 2002. Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication. Antivir. Res. 55:319-329.
23. Herald, B. C., S. I. Gerber, B. J. Belval, A. M. Siston, and N. Shulman. 1996. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry. J. Virol. 70:3461-3469.
24. Herald, B. C., S. I. Gerber, T. Polonsky, B. J. Belval, P. N. Shaklee, and K. Holme. 1995. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding. Virology 206:1108-1116.
25. Herald, B. C., I. Scordi-Bello, N. Cheshenko, D. Marcellino, M. Dzuzelewski, F. Francois, R. Morin, V. Mas Casullo, R. A. Anderson, C. Chany, D. P. Walker, L. J. D. Zaneveld, and M. E. Klotman. 2002. Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J. Virol. 76:11236-11244.
26. Herald, B. C., A. Siston, J. Bremer, R. Kirkpatrick, G. Wilbanks, P. Fugedi, C. Peto, and M. Cooper. 1997. Sulfated carbohydrate compounds prevent microbial adherence by sexually transmitted disease pathogens. Antimicrob. Agents Chemother. 41:2776-2780.
27. Herald, B. C., R. J. Visalli, N. Susmarski, C. R. Brandt, and P. G. Spear. 1994. Glycoprotein-C independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. J. Gen. Virol. 75:1211-1222.
28. Herald, B. C., D. Wudunn, N. Soltus, and P. G. Spear. 1991. Glycoprotein C of herpes simplex virus type 1 plays a principle role in the adsorption of virus to cells and infectivity. J. Virol. 65:1090-1098.
29. Highlander, S., S. L. Sutherland, P. J. Gage, D. C. Johnson, M. Levine, and J. C. Glorioso. 1987. Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J. Virol. 61:3356-3364.
30. Jenssen, H., J. Andersen, D. Mantzilas, and T. J. Gutteberg. 2004. A wide range of medium-sized, highly cationic, α-helical peptides show antiviral activity against herpes simplex virus. Antivir. Res. 64:119-126.
31. Jenssen, H., J. H. Andersen, L. Uhlin-Hansen, T. J. Gutteberg, and O. Rekdal. 2004. Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antivir. Res. 61:101-109.
32. Junakar, P. R., and R. J. Cherry. 1986. Temperature and pH dependence of the haemolytic activity of influenza virus and of the rotational mobility of the spike glycoproteins. Biochim. Biophys. Acta 854:198-206.
33. Leikina, E., H. Delanoe-Ayri, K. Melikov, M.-S. Cho, A. Chen, A. J. Waring, W. Wang, Y. Xie, J. A. Loo, R. I. Lehrer, and L. V. Chernomordik. 2005. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol. 6:995-1001.
34. Liesegang, T. J. 2001. Herpes simplex virus epidemiology and ocular importance. Cornea 20:1-13.
35. Maguire, R. A., N. Bergman, and D. M. Phillips. 2001. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex. Transm. Dis. 28:259-265.
36. Marchetti, M., E. Trybala, F. Superti, M. Johansson, and T. Bergstrom. 2004. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology 318:405-413.
37. Mertz, G. J., R. Ashley, R. L. Burke, J. Benedetti, C. Critchlow, C. C. Jones, and L. Corey. 1989. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J. Infect. Dis. 161:653-660.
38. Montgomery, R. I., M. S. Warner, B. J. Lum, and P. G. Spear. 1996. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-436.
39. Nealon, K., W. W. Newcomb, T. R. Pray, C. S. Craik, J. C. Brown, and D. H. Kedes. 2001. Lytic replication of Kaposi's sarcoma-associated herpesvirus results in the formation of multiple capsids species: isolation and molecular characterization of A, B, and C capsids from a gammaherpesvirus. J. Virol. 75:2866-2878.
40. Nyberg, K., M. Eklblad, T. Bergstrom, C. Freeman, N. Bergman, C. R. Parish, V. Ferro, and E. Trybala. 2004. The low molecular weight heparan sulfate mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus. Antivir. Res. 63:15-24.
41. Okazaki, K., and H. Kida. 2004. A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication. J. Gen. Virol. 85:2131-2137.
42. Patel, R. 2004. Antiviral agents for the prevention of the sexual transmission of herpes simplex in discordant couples. Curr. Opin. Infect. Dis. 17:45-48.
43. Pope, L. E., J. F. Marcelletti, L. R. Katz, Y. Y. Lin, D. H. Katz, M. L. Parish, and P. G. Spear. 1998. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antivir. Res. 40:85-94.
44. Richard, J. P., K. Melikov, E. Vives, C. Ramos, B. Verbeure, M. J. Gail, L. V. Chernomordik, and B. Lebleu. 2003. Cell penetrating peptides. J. Biol. Chem. 278:585-590.
45. Roizman, B., and D. M. Knipe. 2001. Herpes simplex viruses and their replication, p. 2399-2460. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
46. Sacks, S. L., P. D. Griffiths, L. Corey, C. Cohen, A. Cunningham, G. M. Dusheiko, S. Self, S. Spruance, L. R. Stanberry, A. Wald, and R. J. Whitley. 2004. HSV-2 transmission. Antivir. Res. 63(Suppl. 1):S27-S35.
47. Sanna, P. P., A. DeLogu, R. A. Williamson, Y.-L. Horn, S. E. Straus, F. E. Bloom, and D. R. Burton. 1996. Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV. Virology 215:101-106.
48. Schwartz, J. A., E. K. Lium, and S. J. Silverstein. 2001. Herpes simplex virus type 1 entry is inhibited by the cobalt chelate complex CTC-96. J. Virol. 75:4117-4128.
49. Sinha, S., N. Cheshenko, R. I. Lehrer, and B. C. Herald. 2003. NP-1, a rabbit α-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. J. Virol. 47:494-500.
50. Spear, P. G., R. J. Eisenberg, and G. H. Cohen. 2000. Three classes of cell surface receptors for alphaherpes virus entry. Virology 275:1-8.
51. Spear, P. G., and R. Longnecker. 2003. Herpesvirus entry: an update. J. Virol. 77:10179-10185.
52. Stanberry, L. R. 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11:161A-169A.
53. Sumner-Smith, M., Y. Zheng, Y. P. Zhang, E. M. Twist, and S. C. Clime. 1995. Antiherpetic activities of N-α-acetyl-nona-D- arginine amide acetate. Drugs Exp. Clin. Res. XXI:1-6.
54. Tam, J. P., C.-R. Wu, W. Liu, and J.-W. Zhang. 1991. Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am. Chem. Soc. 113:6657-6662.
55. Tyagi, M., M. Rusnati, M. Presta, and M. Giacca. 2001. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276:3254-3261.
56. Wadia, J. S., R. V. Stan, and S. F. Dowdy. 2004. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10:310-315.
57. Wang, W., A. M. Cole, T. Hong, A. J. Waring, and R. I. Lehrer. 2003. Retrocyclin, an antiretroviral θ-defensin, is a lectin. J. Immunol. 170:4708-4716.
58. Wang, W., S. M. Owen, D. L. Rudolph, A. M. Cole, T. Hong, A. J. Waring, R. B. Lal, and R. I. Lehrer. 2004. Activity of α- and θ-defensins against primary isolates of HIV-1. J. Immunol. 173:515-520.
59. Wender, P. A., D. J. Mitchell, K. Pattabiraman, E. T. Pelkey, L. Steinman, and J. B. Rothbard. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97:13003-13008.
60. Whaley, K. J., L. Zeitlin, R. A. Barratt, T. E. Hoen, and R. A. Cone. 1994. Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. J. Infect. Dis. 169:647-649.
61. Whitley, R. J. 1996. Herpes simplex viruses, p. 2297-2342. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, PA.
62. Yanagishita, M., and V. C. Hascall. 1992. Cell surface heparin sulfate proteoglycans. J. Biol. Chem. 267:9451-9454.
63. Yasin, B., W. Wang, M. Pang, N. Chesenko, T. Hong, A. J. Waring, B. C. Herald, E. A. Wagar, and R. I. Lehrer. 2004. θ-Defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78:5147-5156.
64. Ziegler, A., and J. Seelig. 2004. Interaction of the protein transduction domain of HIV-1 TAT with heparan sulfate: binding mechanism and thermodynamic parameters. Biophys. J. 86:252-263.